搜索筛选:
搜索耗时1.3191秒,为你在为你在102,285,761篇论文里面共找到 10 篇相符的论文内容
发布年度:
Lack of association between BIM deletion polymorphism and clinical efficacy of EGFR-TKIs in NSCLC ba
[会议论文] 作者：Siyang Liu,Yilong Wu,
来源：2019中国肿瘤学大会 年份：2019
...
Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure
[期刊论文] 作者：Yilong Wu Jinji Yang Yujuan Hu,
来源：中德临床肿瘤学杂志：英文版 年份：2008
客观我们在化疗和 gefitinib 的失败以后与先进非小的房间肺癌症(NSCLC ) 在病人与 docetaxel 进行了单个代理人的抢救化疗的未来的阶段 II 试用在这个背景估计 docetaxel 的...
[期刊论文] 作者：Yilong Wu,Jinji Yang,Yujuan Hu,
来源：中德临床肿瘤学杂志（英文版） 年份：2004
Objective:We conducted a prospective phase Ⅱ trial of single-agent salvage chemotherapy with docetaxel in patients with advanced non-small cell lung cancer (NS...
A multicenter randomized phase Ⅲ study of Polymeric micelle paclitaxel(pm-Pac)/cisplatin compared wi
[会议论文] 作者：Baohui Han,Qi Shimei,Yilong Wu,
来源：2019中国肿瘤学大会 年份：2019
Objective Background: Paclitaxel/cisplatin is one of the standard chemotherapies for non–small cell lung carcinoma.However,the solvents related adverse effects such as severe allergic reaction,histami...
Comparing overall survival between first generation EGFR-TKIs and chemotherapy in lung cancer patien
[期刊论文] 作者：Wei Deng,Yuanyuan Lei,Siyang Liu,Jinji Yang,Haiyan Tu,Honghong Yan,Yilong Wu,,
来源：Chinese Journal of Cancer Research 年份：2016
Objective: Combined overall survival(OS) analysis of Lux-Lung 3 and Lux-Lung 6 demonstrated that patients with epidermal growth factor receptor(EGFR) exon 19 de...
[会议论文] 作者：Wei Li,Wenzhao Zhong,Xuening Yang,Riqiang Liao,Qiang Nie,Song Dong,Jin-ji Yang,Yilong Wu,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: The progression of pulmonary ground glass nodules (GGNs) was slow, 5 years survival rate of lobe/sublobe resection was close to 100%.In clinical, we also found that the progression of some...
Phase Ⅱ trial comparing tepotinib + gefitinib with cisplatin + pemetrexed in Asian patients with gef
[会议论文] 作者：Yilong Wu,Keunchil Park,Dongwan Kim,Ross a.Soo,Cindy Li,Huiling Xiong,Christian Ihling,James chih-hsin,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Background: The combination of the highly selective c-Met inhibitor tepotinib (MSC2156119J) + gefitinib was shown to be well tolerated and have antitumor activity possibly associated with c-Met-positi...
An exploratory study on the optimal chemotherapy regimen for NSCLC patients with EGFR common mutatio
[会议论文] 作者：xuewu wei,Yunting He,Ee KE,Haiyan Tu,Jinji Yang,Wenzhao Zhong,Xuchao Zhang,Yilong Wu,Qing Zhou,
来源：2019中国肿瘤学大会 年份：2019
Objective EGFR-TKIs have been the first-line treatment for advanced non-small cell lung cancer patients with EGFR mutations.Chemotherapy remains the standard treatment for patients without T790M mutat...
[会议论文] 作者：Gao,Jinji Yang,Zhihong Chen,Anna Li,Xuchao Zhang,Zhi Xie,Jian Su,Juntao Lin,Zhongyi Dong,Yangsi Li,Yilong Wu,
来源：第四届广州国际肿瘤学会议 年份：2015
Background: Immunohistochemistry(IHC)and fluorescent in situ hybridization(FISH)are reliable ways to identify overexpression of c-Met protein or amplification of the c-Met gene,but each technique requ...
Molecular alterations in cerebrospinal fluid predict clinical outcomes of central nervous system met
[会议论文] 作者：Benyuan Jiang,Haiyan Tu,Junyi Ye,Jinji Yang,Xuchao Zhang,Shannon Chuai,Hao Sun,Qing Zhou,Wenzhao Zhong,Yilong Wu,
来源：2019中国肿瘤学大会 年份：2019
Objective Brain metastases(BM)occurs in up to 44%of non-small-cell lung cancer(NSCLC)patients and are associated with a poor prognosis with a median overall survival 4–15 months in treated patients....
相关搜索：
